Cell Design Labs Envisions Robot Control of Tomorrow's CAR-T Therapies

Emerging Company Profile: San Francisco startup aligned with Kite Pharma believes T-cells may be programmed to reversibly activate and deactivate, greatly improving specificity, efficacy and safety of chimeric antigen receptor T-cell therapies.

Using a deal with CAR-T frontrunner Kite Pharma Inc. as a springboard, San Francisco-based start-up Cell Design Labs hopes to bring forward a new generation of specific, reversible T-cell therapies as an alternative to the imprecise, explosive nature of the candidates tested to date.

Kite Pharma, Juno Therapeutics Inc. and Novartis AG have been at the forefront of development for chimeric antigen...

More from Start-Ups & SMEs

More from Business

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By 

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.